Avitide Plants Flag at Former Merck Location
The affinity purification company will set up shop at the former Merck & Co./GlycoFi facility in the Dartmouth Regional Technology Center in New Hampshire.
Avitide has a new headquarters for all of its affinity resin discovery and manufacturing operations, according to a July 27, 2016 release from the company. It expanded its operations at the Dartmouth Regional Technology Center to move into the spot formerly occupied by Merck subsidiary GlycoFi. The move will allow Avitide to quadruple the company’s R&D capabilities, according to Kevin Isett, CEO and co-founder.
Avitide offers affinity separation technology for the downstream purification of biopharmaceuticals such as protein-based products and vaccines. It delivers bespoke, on-demand solutions to clients in a three-month period. “Securing this long-term facility agreement reinforces Avitide’s commitment to become the world-leader in exclusive affinity separation technologies for preclinical, clinical, and commercial biologics, vaccines, and gene therapies,” said Isett in a press release.
Source: Business Wire
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
